These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2478654)

  • 1. Human immunodeficiency virus 1. Predominance of a group-specific neutralizing epitope that persists despite genetic variation.
    Berkower I; Smith GE; Giri C; Murphy D
    J Exp Med; 1989 Nov; 170(5):1681-95. PubMed ID: 2478654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human immunodeficiency virus 1: predominance of a group-specific neutralizing epitope that persists despite genetic variation.
    Dis Markers; 1990; 8(2):105-7. PubMed ID: 1696869
    [No Abstract]   [Full Text] [Related]  

  • 3. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.
    Zhang PF; Bouma P; Park EJ; Margolick JB; Robinson JE; Zolla-Pazner S; Flora MN; Quinnan GV
    J Virol; 2002 Jan; 76(2):644-55. PubMed ID: 11752155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of neutralizing and enhancing antibodies to human immunodeficiency virus type 1 primary isolates in plasma of individuals infected with env Genetic subtype B and E viruses in Thailand.
    Auewarakul P; Louisirirotchanakul S; Sutthent R; Taechowisan T; Kanoksinsombat C; Wasi C
    Viral Immunol; 1996; 9(3):175-85. PubMed ID: 8890476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1.
    Javaherian K; Langlois AJ; Schmidt S; Kaufmann M; Cates N; Langedijk JP; Meloen RH; Desrosiers RC; Burns DP; Bolognesi DP
    Proc Natl Acad Sci U S A; 1992 Feb; 89(4):1418-22. PubMed ID: 1371358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
    Li H; Zony C; Chen P; Chen BK
    J Virol; 2017 May; 91(9):. PubMed ID: 28148796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of epitope position on neutralization by anti-human immunodeficiency virus monoclonal antibody 2F5.
    Ou W; Lu N; Yu SS; Silver J
    J Virol; 2006 Mar; 80(5):2539-47. PubMed ID: 16474160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.
    Townsley S; Li Y; Kozyrev Y; Cleveland B; Hu SL
    J Virol; 2016 Jan; 90(2):829-41. PubMed ID: 26512079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralization of human immunodeficiency virus type 1 (HIV-1) with antibody from carriers' plasma against HIV-1 protein p17.
    Kageyama S; Katsumoto T; Taniguchi K; Ismail SI; Shimmen T; Sasao F; Gao M; Owatari S; Wakamiya N; Tsuchie H; Ueda S; Shiraki K; Kurimura T
    Acta Virol; 1996 Sep; 40(4):195-200. PubMed ID: 9014009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1.
    Armstrong SJ; McInerney TL; McLain L; Wahren B; Hinkula J; Levi M; Dimmock NJ
    J Gen Virol; 1996 Dec; 77 ( Pt 12)():2931-41. PubMed ID: 9000083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new cell line-based neutralization assay for primary HIV type 1 isolates.
    Shi Y; Albert J; Francis G; Holmes H; Fenyö EM
    AIDS Res Hum Retroviruses; 2002 Sep; 18(13):957-67. PubMed ID: 12230938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to infection by HIV-1 of peripheral blood mononuclear cells from HIV-1-infected patients is probably mediated by neutralizing antibodies.
    Tremblay M; Numazaki K; Li XG; Gornitsky M; Hiscott J; Wainberg MA
    J Immunol; 1990 Nov; 145(9):2896-901. PubMed ID: 1698866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Neutralizing antibodies to 5 HIV-1 strains in macaques immunized with the multi-epitope polypeptide TAB9].
    Navea Leyva LM; Lobaina Bartelemy L; Dubed Echevarría M; Alvarez Seguí G; Gómez Rodríguez C; Duarte Cano C
    Rev Cubana Med Trop; 2000; 52(2):115-8. PubMed ID: 11107905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigenicity and predefined specificities of the multi-epitope vaccine in candidate consisting of neutralizing epitope and mutated epitopes suggested a new way against HIV-1 mutation.
    Tian H; Xiao Y; Qin L; Chen YH
    Immunobiology; 2001 Dec; 204(4):434-41. PubMed ID: 11776398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epitopes of the HIV-1-negative factor (nef) reactive with murine monoclonal antibodies and human HIV-1-positive sera.
    Schneider T; Harthus HP; Hildebrandt P; Niedrig M; Bröker M; Weigelt W; Beck A; Pauli G
    AIDS Res Hum Retroviruses; 1991 Jan; 7(1):37-44. PubMed ID: 1707640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenic and antigenic dominance of a nonneutralizing epitope over a highly conserved neutralizing epitope in the gp41 envelope glycoprotein of human immunodeficiency virus type 1: its deletion leads to a strong neutralizing response.
    Cleveland SM; Buratti E; Jones TD; North P; Baralle F; McLain L; McInerney T; Durrani Z; Dimmock NJ
    Virology; 2000 Jan; 266(1):66-78. PubMed ID: 10612661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a new neutralizing epitope conformationally affected by the attachment of CD4 to gp120.
    Kang CY; Hariharan K; Posner MR; Nara P
    J Immunol; 1993 Jul; 151(1):449-57. PubMed ID: 7686944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
    Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epitopes corresponding to the envelope genetic subtype are present on the surface of free virions of HIV-1 group M primary isolates and can be detected in neutralization assays with extended incubation phases.
    Davis D; Donners H; Willems B; Vermoesen T; Heyndrickx L; Colebunders R; van der Groen G
    J Med Virol; 2003 Nov; 71(3):332-42. PubMed ID: 12966537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.